Table 6.

Ongoing clinical trials combining IT therapies with PD-1/PD-L1 blockade.

Class of IT (n)	Subtype	Reference
Cytotoxic agents (31)	Adoptive T cell therapy	NCT01174121, NCT02775292, NCT02595866, NCT02858310, NCT02652455, NCT02652455, NCT01993719, NCT02500576, NCT02621021, NCT02706405, NCT02926833, NCT02973113, NCT02757391, NCT01822652, NCT02584829
	Oncolytic viruses	NCT03003676, NCT02636036, NCT01986426, NCT02798406, NCT02565992, NCT02043665, NCT02824965, NCT02620423, NCT02963831, NCT02919449, NCT02626000, NCT02965716, NCT02263508, NCT02978625, NCT03071094, NCT03069378
Cytokines (33)	Interferons	NCT02584829, NCT02614456, NCT02982720, NCT02859324, NCT02112032, NCT02339324, NCT02174172, NCT02089685, NCT03063632
	IL-2	NCT02650713, NCT02748564, NCT02983045, NCT02964078, NCT02989714, NCT02350673, NCT03111901, NCT03063762
	Others	NCT02900664, NCT02523469, NCT02703714, NCT02009449, NCT02994953, NCT02493361, NCT02947165, NCT02423343, NCT02734160, NCT02933944, NCT02339571, NCT02383212, NCT03111992, NCT03030378, NCT03132675, NCT03136406
T cell costimulation (29)	4-1BB (CD137)	NCT02652455, NCT02554812, NCT02253992, NCT02179918, NCT02534506, NCT02845323, NCT02658981, NCT02951156
	CD40	NCT02733042, NCT02304393, NCT02955251, NCT02706353, NCT02719015, NCT03123783
	Miscellaneous	NCT02335918, NCT02543645, NCT02740270, NCT02132754, NCT02553499, NCT02598960, NCT02723955, NCT02904226, NCT03038672, NCT03126110
	OX40 (CD134)	NCT02221960, NCT02528357, NCT02705482, NCT02737475, NCT02410512, NCT02554812, NCT03029832
T cell coinhibition (27)	A2 a/CD73	NCT02740985, NCT02655822, NCT02403193, NCT02503774, NCT02754141, NCT03099161, NCT03094637
	LAG3	NCT02658981, NCT01968109, NCT02460224, NCT02966548, NCT03005782, NCT02676869, NCT02061761, NCT02750514, NCT02060188, NCT02935634, NCT02996110
	Misc.	NCT02794571, NCT02913313, NCT02608268, NCT02817633, NCT02118337, NCT02936102, NCT02475213, NCT03099109, NCT03066648
Miscellaneous (22)	STAT3, BITE, mTOR, BCG, steroids, et al.	NCT02988960, NCT02324582, NCT02792192, NCT02808143, NCT02665650, NCT02651662, NCT02546661, NCT02990416, NCT02983578, NCT02930902, NCT02659384, NCT02669914, NCT02890069, NCT02879695, NCT02423954, NCT02259231, NCT02499328, NCT02549651, NCT02495636, NCT03071757, NCT03048500, NCT03155061
Inhibitors of immunosuppression (33)	Anti-CSF	NCT02452424, NCT02323191, NCT02526017, NCT02713529, NCT02829723, NCT02880371, NCT02777710, NCT02807844, NCT02554812, NCT02718911
	CTX (Tregs)	NCT02901145, NCT02768701, NCT02406781, NCT02298946, NCT02853318, NCT03003676, NCT03139851, NCT03029403
	IDO	NCT02178722, NCT02318277, NCT02327078, NCT02471846, NCT02658890, NCT02862457, NCT02073123, NCT02298153, NCT03085914, NCT03006302, NCT02959437, NCT02752074
	Miscellaneous	NCT02981303, NCT03003468, NCT02903914
Epigenetic agents (37)	Azacitidine	NCT02959437, NCT02811497, NCT02260440, NCT02900560, NCT02816021, NCT02951156, NCT02530463, NCT02599649, NCT02281084, NCT02508870, NCT02775903, NCT02397720, NCT02953561, NCT01928576, NCT02546986, NCT02664181, NCT02117219, NCT03092674, NCT03019003
	HDAC inhibitors	NCT02805660, NCT02909452, NCT02708680, NCT02538510, NCT02993991, NCT02935790, NCT02697630, NCT02936752, NCT02437136, NCT02638090, NCT02915523, NCT02718066, NCT02619253, NCT02890069, NCT02954991, NCT01928576, NCT02453620, NCT02635061, NCT02395627, NCT03024437
Chemokines (12)	CCR's	NCT02301130, NCT02476123, NCT02705105, NCT02946671, NCT02723006
	CXC's	NCT02472977, NCT02737072, NCT02823405, NCT02826486, NCT02923531, NCT02583477, NCT02499328
Innate IT (18)	Natural killer	NCT01714739, NCT02843204, NCT02671435, NCT02599649, NCT01592370, NCT03023527
	TLRs/STING	NCT03009058, NCT02124850, NCT02834052, NCT02521870, NCT02644967, NCT02680184, NCT02501473, NCT03007732, NCT02431559, NCT02643303 NCT03010176, NCT03084640
Vaccines (51)	Miscellaneous	NCT02291055, NCT02955290, NCT02325557, NCT02499835, NCT03136406, NCT03122548, NCT03100006
	Dendritic cell	NCT02529072, NCT01067287, NCT02677155, NCT02886897, NCT03014804, NCT03059485, NCT03024216, NCT03035331, NCT03092453
	Peptide	NCT01176461, NCT01176474, NCT02426892, NCT02764333, NCT02535078, NCT02515227, NCT02897765, NCT02826434, NCT02886065, NCT02737787, NCT02609984, NCT03029403, NCT03121677, NCT03047928, NCT03018288
	Tumor-derived	NCT02466568, NCT02981524, NCT02243371, NCT03006302, NCT02648282, NCT02451982, NCT02054520, NCT02439450, NCT02725489, NCT02574533, NCT02639234, NCT03073525, NCT03113487, NCT03050814
	Virus	NCT02840994, NCT02122861, NCT02879760, NCT02823990, NCT02609984, NCT02432963, NCT02933255

^*Some trials are treating with more than one agent of an IT type and were listed twice. Abbreviations: A2 a = adenosine A2 a receptor, BCG = Bacillus Calmette-Guerin, BITE = Bispecific T cell engager, CCR = CC chemokine receptor, CSF = colony stimulating factor, CTX = cyclophosphamide, CXC = CXC motif, LAG3 = lymphocyte-activation gene 3, IDO = indoleamine 2,3-dioxygenase, IT = immunotherapy, mTOR = mammalian target of rapamycin, Tregs = regulatory T cells, Misc. = miscellaneous, HDAC = histone deacetylase, STAT3 = signal transducer and activator of transcription 3, TLR = toll-like receptor, STING = stimulator of interferon genes.